KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Payables (2016 - 2025)

Gsk (GSK) has 8 years of Payables data on record, last reported at $22.7 billion in Q4 2024.

  • For Q4 2024, Payables fell 1.91% year-over-year to $22.7 billion; the TTM value through Dec 2024 reached $22.7 billion, down 1.91%, while the annual FY2024 figure was $22.6 billion, 2.52% down from the prior year.
  • Payables reached $22.7 billion in Q4 2024 per GSK's latest filing, down from $23.1 billion in the prior quarter.
  • Across five years, Payables topped out at $28.5 billion in Q4 2021 and bottomed at $22.7 billion in Q4 2024.
  • Average Payables over 4 years is $24.5 billion, with a median of $23.4 billion recorded in 2022.
  • Peak YoY movement for Payables: fell 16.85% in 2022, then dropped 1.91% in 2024.
  • A 4-year view of Payables shows it stood at $28.5 billion in 2021, then decreased by 16.85% to $23.7 billion in 2022, then fell by 2.41% to $23.1 billion in 2023, then decreased by 1.91% to $22.7 billion in 2024.
  • Per Business Quant database, its latest 3 readings for Payables were $22.7 billion in Q4 2024, $23.1 billion in Q4 2023, and $23.7 billion in Q4 2022.